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Abstract 
Purpose: To describe the epidemiology of intra‑abdominal infection in an international cohort of ICU patients 
according to a new system that classifies cases according to setting of infection acquisition (community‑acquired, 
early onset hospital‑acquired, and late‑onset hospital‑acquired), anatomical disruption (absent or present with local‑
ized or diffuse peritonitis), and severity of disease expression (infection, sepsis, and septic shock).
Methods: We performed a multicenter (n = 309), observational, epidemiological study including adult ICU patients 
diagnosed with intra‑abdominal infection. Risk factors for mortality were assessed by logistic regression analysis.
Results: The cohort included 2621 patients. Setting of infection acquisition was community‑acquired in 31.6%, early 
onset hospital‑acquired in 25%, and late‑onset hospital‑acquired in 43.4% of patients. Overall prevalence of antimicro‑
bial resistance was 26.3% and difficult‑to‑treat resistant Gram‑negative bacteria 4.3%, with great variation according 
to geographic region. No difference in prevalence of antimicrobial resistance was observed according to setting of 
infection acquisition. Overall mortality was 29.1%. Independent risk factors for mortality included late‑onset hospital‑
acquired infection, diffuse peritonitis, sepsis, septic shock, older age, malnutrition, liver failure, congestive heart 
failure, antimicrobial resistance (either methicillin‑resistant Staphylococcus aureus, vancomycin‑resistant enterococci, 
extended‑spectrum beta‑lactamase‑producing Gram‑negative bacteria, or carbapenem‑resistant Gram‑negative 
bacteria) and source control failure evidenced by either the need for surgical revision or persistent inflammation.
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Introduction
Severe intra-abdominal infections are a frequent and 
important issue in intensive care (ICU). According to 
international literature, the abdomen often ranks first or 
second among the sources of infection or sepsis [1–3].
Intra-abdominal infections pose several particular 
clinical challenges. First, there is a large span of disease 
severity ranging from uncomplicated cases to fulmi-
nant septic shock and multi-organ dysfunction. Second, 
there is the broad spectrum of pathogens including 
Gram-positive and Gram-negative aerobic bacteria, 
anaerobes, and fungi [4]. Third, the contribution of 
microbiological diagnosis is not straightforward as 
cultures cannot always readily discriminate true path-
ogens from harmless micro-organisms [5, 6]. Further-
more, source control encompassing all interventions to 
eradicate the source of infection, control on-going con-
tamination, and to restore anatomic derangements and 
physiologic function, is key to clinical management and 
success, but often difficult to achieve [5, 7, 8]. Finally, 
there is the wide variety of clinical entities within intra-
abdominal infections. Besides local abscess forma-
tion or solid organ infection (e.g., liver abscesses and 
infected pancreatic necrosis), a classic approach recog-
nizes three types of peritonitis: i.e., primary peritoni-
tis (peritoneal dialysis-related or spontaneous bacterial 
peritonitis), secondary peritonitis (following anatomi-
cal disruption of the GI tract), or tertiary peritonitis 
(persistent infection despite adequate source control 
intervention). In addition, cases of intra-abdominal 
infection are often classified as uncomplicated or com-
plicated. Complicated describes extension of infection 
from their source into the peritoneal cavity.
Because of this heterogeneity, the intra-abdominal 
infections are difficult to study [9]. To bring more clar-
ity in the terminology, an alternative classification for 
intra-abdominal infections has been proposed [10]. This 
system classifies intra-abdominal infections accord-
ing to their setting of acquisition (community-acquired, 
healthcare-associated or early onset hospital-acquired, 
or late-onset hospital-acquired), presence of anatomical 
disruption (either absent or present resulting in localized 
or diffuse peritonitis), and severity of disease expression 
(infection, sepsis, or septic shock). This classification 
defines different phenotypes of the same disease (e.g., 
diverticulitis) by covering aspects of (i) the extent of 
intra-abdominal contamination reflecting the complex-
ity of source control, (ii) level of associated organ failure 
indicating sense of urgency and prognosis, and (iii) likeli-
hood of antimicrobial resistant micro-organisms or oth-
erwise important pathogens which may require broader 
antimicrobial coverage (enterococci, Candida spp.).
The objective of the study was to describe the epide-
miology of intra-abdominal infection in an international 
cohort of ICU patients and to validate the predictive 
value for mortality of an alternative classification system.
Methods
A complete version of the Methods is in Supplement-1. 
AbSeS was an international, multicenter, prospective 
observational cohort study conducted between January 
and December 2016. Consecutive, adult ICU patients 
diagnosed with intra-abdominal infection, either as pri-
mary diagnosis leading to ICU admission or as a com-
plication occurring during the ICU course, were eligible 
for inclusion. Overall, approval by established national, 
regional, or local institutional review boards was expe-
dited and granted. The study is registered at ClinicalTri-
als.gov (number NCT03270345).
Data recorded and definitions
We obtained data describing the hospital and intensive-
care facility through a center report form. Anonymous 
patient data were collected through the case report 
form. Examples of the center and case report forms are 
in Supplement-2. Type of intra-abdominal infection was 
defined according to the International Sepsis Forum 
Consensus Conference Definitions [11]. Intra-abdominal 
infections were classified according to setting of infection 
Conclusion: This multinational, heterogeneous cohort of ICU patients with intra‑abdominal infection revealed that 
setting of infection acquisition, anatomical disruption, and severity of disease expression are disease‑specific pheno‑
typic characteristics associated with outcome, irrespective of the type of infection. Antimicrobial resistance is equally 
common in community‑acquired as in hospital‑acquired infection.
Keywords: Intra‑abdominal infection, Peritonitis, Sepsis, Intensive care, Multidrug resistance, Mortality
Key message 
A multinational epidemiological study on intra‑abdominal infec‑
tion in ICU patients revealed that setting of infection acquisition, 
anatomical barrier disruption, and severity of disease expression 
are disease‑specific phenotypic characteristics associated with 
mortality.
Antibiotic resistance appeared equally in community‑acquired as in 
hospital‑acquired infection.
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acquisition, anatomical barrier disruption, and severity of 
disease expression [10]. Setting is community-acquired, 
healthcare-associated and/or early onset hospital-
acquired (≤ 7  days of hospital admission), or late-onset 
hospital-acquired (> 7  days of hospital admission [12]). 
Healthcare-associated onset is defined by at least one of 
the following risk factors for multidrug-resistant patho-
gens: nursing home resident, out-of-hospital parenteral 
nutrition or vascular access, chronic dialysis, recent 
hospital admission (< 6 months), or recent antimicrobial 
therapy (< 6 months). For convenience sake, ‘healthcare-
associated and/or early-onset hospital-acquired’ cases are 
designated ‘early-onset hospital-acquired’. Intra-abdomi-
nal infections were classified as either without anatomi-
cal disruption, or with anatomical disruption resulting in 
localized or diffuse peritonitis (i.e., contamination spread 
to entire abdominal cavity). Severity of disease expression 
is defined as either infection, sepsis, or septic shock [13]. 
Microbiological assessment was left at the discretion of 
the physician. Eligible cultures included intra-operative 
cultures, trans-abdominal fine-needle aspiration, blood 
cultures presumably related to the intra-abdominal infec-
tion, and cultures from abdominal drains sampled ≤ 24 h 
post-surgery. Thresholds for resistance were those as 
reported by The European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) [14]. Antimicro-
bial resistance was defined as methicillin resistance 
for Staphylococcus aureus, vancomycin resistance for 
enterococci, and for Gram-negative bacteria either pro-
duction of extended-spectrum beta-lactamase (ESBL), 
carbapenem resistance, or fluoroquinolone resistance 
(resistance against ciprofloxacin, levofloxacin, or moxi-
floxacin). To assess relationships between resistance and 
mortality, we also used the definition of “difficult-to-
treat” resistance for Gram-negative bacteria. This com-
bines resistance to all tested carbapenem, beta-lactam, 
and fluoroquinolone agents, and is associated with worse 
clinical outcomes in bloodstream infection [15, 16]. We 
deviated from this definition, however, using ESBL pro-
duction as a proxy for resistance against penicillins, 
cephalosporins, and monobactams. For reporting micro-
biological results, the number of patients with cultures 
sampled is used as denominator. Data on anti-infective 
management included antimicrobial therapy and source 
control. Antimicrobial coverage of empiric therapy was 
evaluated for basic coverage (i.e., coverage of Gram-
positive, Gram-negative, and anaerobic bacteria), and 
the association of an antimicrobial agent or initial choice 
with potential clinical activity against Pseudomonas aer-
uginosa, methicillin-resistant S. aureus (MRSA), ente-
rococci, vancomycin-resistant enterococci (VRE), and 
Candida. In this regard, coverage of enterococci targets 
Enterococcus faecalis [6]. Outcome data included source 
control assessment 7 days post-diagnosis or earlier if the 
patient died within that time window. Source control was 
judged as either successful or having failed. Failure rep-
resented either persistent inflammation (clinical evidence 
of a remaining source of infection) or the necessity of 
re-intervention following the initial approach (conserva-
tive management or source control intervention). Main 
outcome is ICU mortality with a minimum of 28 days of 
observation.
Data management and statistical analyses
Simple descriptive statistics were used to characterize the 
study population; continuous data were summarized by 
median and interquartile range, categorical data as n (%). 
Logistic regression analysis was used to assess relation-
ships with mortality. Details on the regression models 
are in Supplement-1. It can be considered inappropriate 
to include ‘source control achievement at day 7’ in the 
model as this covariate is instrumental to the biological 
pathway between infection onset and mortality. There-
fore, we report a logistic regression model with and with-
out source control achievement.
Results
During the study period, 2850 patients were included; 
229 were excluded, because essential data were miss-
ing. As such, 2621 patients from 309 ICUs from 42 
countries were entered for analysis. Most patients were 
included in various European regions (n = 1830; 69.8%), 
followed by Middle & South America (n = 366; 14.0%), 
North Africa & Middle-East (n = 214; 8.8%), Asia-
Pacific (n = 174; 6.6%), North America (n = 29; 1.1%), 
and Sub-Saharan Africa (n = 8; 0.3%) (Supplement-3).
Characteristics of the study cohort according to set-
ting of infection acquisition are reported in Table  1. 
Setting of infection acquisition was community-
acquired in 828 patients (31.6%), early onset hospi-
tal-acquired in 656 patients (25.0%), and late-onset 
hospital-acquired in 1137 patients (43.4%). Underly-
ing conditions were more frequently observed in cases 
with healthcare-associated or hospital-acquired infec-
tion. Cases with hospital-acquired infection had higher 
SOFA scores and more often septic shock.
The vast majority of cases involved secondary perito-
nitis (68.4%), followed by biliary tract infection (12.2%), 
intra-abdominal abscess (6.9%), and pancreatic infec-
tion (6.3%). Primary peritonitis, toxic megacolon, peri-
toneal dialysis-related peritonitis, and typhlitis were 
less frequent (< 4%). Details on the distribution accord-
ing to setting of infection acquisition are reported in 
Table 2.
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Microbiology
Microbiological samples were obtained in 1982 patients 
(75.6%). In 80.4% of these patients, at least one cul-
ture was found positive (n = 1594). Figure 1 reports the 
type of samples obtained with their respective propor-
tion of culture positivity. Gram-negative bacteria were 
most frequently isolated (58.6%) with Enterobacterales 
as predominant family (51.7%) and Escherichia coli as 
most common pathogen (36.8%). Gram-positive aerobic 
bacteria were isolated in 39.4% of patients with entero-
cocci as most prevalent species (25.9%). Furthermore, 
anaerobic bacteria and fungi were isolated in 11.7% 
and 13.0% of patients, respectively. Detailed results 
on isolated micro-organisms are reported in Table  3. 
Multidrug-resistant micro-organisms were isolated 
from 522 patients (26.3%). Antimicrobial resistance 
rates were not different among community-acquired 
(26.5%), early onset hospital-acquired (29.0%), and late-
onset hospital-acquired infection (24.6%) (p = 0.215). 
There was also no difference in antimicrobial resistance 
among patients with infection (27.6%), sepsis (26.9%), 
and septic shock (25.0%) (p = 0.449). Antimicrobial 
resistance is mainly a matter of Gram-negatives, but 
variations according to geographic region are substan-
tial (Table  4). Regions of particular concern include 
Eastern- and South-East Europe, North Africa and the 
Middle-East, and Latin America as > 35% of patients are 
infected by at least one antimicrobial resistant micro-
organism. Antimicrobial resistance rates according to 
setting of infection acquisition and region are reported 
in Supplement-5.
Antimicrobial therapy
Data on the first-line empiric antimicrobial therapy was 
available from 2427 patients (92.6%). A basic sched-
ule covering aerobic Gram-positive, Gram-negative, 
and anaerobic bacteria was prescribed in 2291 patients 
(94.4%). An anti-pseudomonal agent was prescribed in 
1978 patients (81.8%). Empiric coverage of MRSA and 
VRE was added in, respectively, 647 patients (26.7%) and 
140 patients (5.8%). An antifungal agent was associated 
in 436 patients (18%). In 365 patients, two agents with 
anti-anaerobic activity were prescribed (15%). Double 
anti-anaerobic coverage was more frequently prescribed 
in hospital-acquired cases (18.2%) compared with com-
munity-acquired cases (14.2%). No other differences in 
antimicrobial coverage according to setting of infection 
acquisition were observed (Supplement-6).
Source control
Data on the initial approach to control the infection are 
reported in 2438 patients. A source control intervention 
was carried out in 2334 patients (95.7%), and included 
drainage (94.0%), decompressive surgery (7.9%), and 
restoration of anatomy and function (28.2%). Among 
patients undergoing source control, persistent inflam-
mation at day 7 was reported in 692 patients (29.6%). 
An additional intervention was deemed necessary in 382 
patients (16.4%). Among patients with an initial con-
servative approach (n = 104), 30 patients experienced 
persistent inflammation (28.8%), and a source control 
intervention was performed in 5 patients (4.8%). More 
details on source control interventions and evaluations 
are summarized in Fig. 2.
Mortality
Overall mortality was 29.1% (752/2588). Univariate 
relationships with mortality are reported in Supple-
ment-7. Mortality stepwise increased with ascending 
SOFA scores (Supplement-8). Achievement of source 
control at day 7 was associated with lower mortality 
(248/1438, 17.2%) compared with cases with persistent 
inflammation (367/761, 51.8%) and those requiring sur-
gical revision (110/389, 28.3%) (p < 0.001). We reported 
mortality according to setting of infection acquisition, 
anatomical disruption, and severity of disease expres-
sion. Mortality was 23.7% in community-acquired 
cases, 27.3% in early onset hospital-acquired cases, and 
33.9% in late-onset hospital-acquired cases (p < 0.001). 
Regarding anatomical disruption, no difference in 
mortality was observed between patients without ana-
tomical disruption and those with localized peritonitis 
(respectively, 25.0% and 24.2%, p = 0.135). Mortality 
in patients with diffuse peritonitis (36.0%) was higher 
compared with the former categories (p < 0.001). Finally, 
mortality stepwise increased with greater severity of 
disease expression: 12.8% in infected patients without 
sepsis, 24.5% in septic patients, and 40.3% in patients 
with septic shock (p < 0.001). Table 5 reports mortality 
rates for all different phenotypes of intra-abdominal 
infection according to setting of infection acquisition, 
anatomical disruption, and severity of disease expres-
sion. The grid describes a stepwise increase in mortality 
along with combinations including septic shock, diffuse 
peritonitis, and late-onset hospital-acquired infection.
Logistic regression analysis identified late-onset hos-
pital-acquired infection, diffuse peritonitis, sepsis and 
septic shock, older age, malnutrition, diabetes mellitus, 
liver failure, and congestive heart failure as independent 
risk factors for death (Table 6). The association of an anti-
MRSA agent in the empiric antimicrobial scheme was 
associated with decreased risk of death. Antimicrobial 
resistance defined as MRSA, VRE, or difficult-to-treat 
resistant Gram-negatives did not reached the final mod-
els. However, when antimicrobial resistance in Gram-
negative bacteria was defined as either ESBL production 
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Table 1 Patient characteristics of intensive-care unit patients with intra-abdominal infection/sepsis according to setting 
of infection acquisition
Data are reported as n (%) or median (1st–3rd quartile)
SAPS simplified acute physiology score, SOFA sequential organ failure assessment
*p value indicates differences between patients with community-acquired infection, healthcare-associated infection or early onset hospital-acquired infection, and 
late-onset hospital-acquired infection
**Data missing from 29 patients
***More details regarding underlying conditions are reported in Supplement–4
Characteristic Total cohort (n = 2621) Community-acquired (n = 828) Early onset hospital-
acquired (n = 656)
Late-onset hospital-
acquired (n = 1137)
p*
Demographics
Age, years 66 (54–75) 67 (52–77) 66 (54–77) 66 (55–74) 0.213
Sex, male 1488/2615 (56.9) 452 (54.6) 364 (55.5) 672 (59.1) 0.133
Type of ICU admission 2592** 799** 656 1137
 Medical 472 (18.2) 109 (13.7) 131 (20.0) 232 (20.4) <0.001
 Surgical, non‑emergency 233 (9.0) 19 (2.4) 39 (5.9) 175 (15.4) < 0.001
 Surgical, emergency 1847 (71.3) 660 (82.6) 478 (72.9) 709 (62.4) < 0.001
 Trauma 40 (1.5) 11 (1.4) 8 (1.2) 21 (1.8) 0.496
ICU stay, days 9 (4‑18) 9 (4–18) 9 (4–17) 10 (5–19) 0.183
Underlying conditions***
Chronic pulmonary disease 342 (13.0) 96 (11.6) 90 (13.7) 156 (13.7) 0.324
AIDS 14 (0.5) 6 (0.7) 3 (0.5) 5 (0.4) 0.661
Malignancy 699 (26.7) 116 (14.0) 170 (25.9) 413 (36.3) < 0.001
Neurologic disease 165 (6.3) 42 (5.1) 60 (9.1) 75 (6.6) 0.008
Peptic ulcer disease 176 (6.7) 57 (6.9) 52 (7.9) 67 (5.9) 0.246
Liver disease 127 (4.8) 24 (1.5) 44 (6.7) 59 (5.2) 0.002
Chronic renal failure 282 (10.8) 57 (6.9) 100 (15.2) 125 (11.0) < 0.001
Myocardial infarction 188 (7.2) 48 (5.8) 57 (8.7) 83 (7.3) 0.098
Chronic heart failure (NY Heart 
Association class IV)
184 (7.0) 36 (4.3) 64 (9.8) 84 (7.4) < 0.001
Peripheral vascular disease 169 (6.4) 34 (4.1) 48 (7.3) 87 (7.7) 0.004
Diabetes mellitus 488 (18.6) 116 (14.0) 141 (21.5) 231 (20.3) < 0.001
Immunosuppression 253 (9.7) 47 (5.7) 83 (12.7) 123 (10.8) < 0.001
Lifestyle risk factors 1363 (52.0) 413 (49.9) 355 (54.1) 595 (52.3) 0.257
Malnutrition (body mass index < 20) 177 (6.8) 46 (5.6) 53 (8.1) 78 (6.9) 0.154
Obesity (body mass index ≥ 30) 735 (28.0) 236 (28.5) 197 (30.0) 302 (26.6) 0.271
Tobacco use (> 20 pack years) 446 (17.0) 127 (7.1) 106 (16.2) 213 (18.7) 0.113
Alcohol abuse (> 10 g alcohol/day) 196 (7.5) 59 (7.1) 49 (7.5) 88 (7.7) 0.261
IV drug abuse 17 (0.6) 8 (1.0) 3 (0.5) 6 (0.5) –
Severity of acute illness
SAPS II score at time of ICU admis‑
sion
49 (39–60) 48 (38–59) 49 (39–61) 49 (38–60) 0.183
SOFA score at diagnosis 6 (3–10) 5 (3–9) 7 (3–10) 6 (3–10) < 0.001
Severity of disease expression
Infection without sepsis 164 (6.3) 51 (6.2) 42 (6.4) 71 (6.2) 0.981
Sepsis 1590 (60.7) 528 (63.8) 399 (60.8) 663 (58.3) 0.050
Septic shock 867 (33.1) 249 (30.1) 215 (32.8) 403 (35.4) 0.043
Anatomical disruption
Not present 615 (23.5) 186 (22.5) 166 (25.3) 263 (23.1) 0.413
Yes, with localized peritonitis 981 (37.4) 342 (41.3) 256 (39.0) 383 (33.7) 0.002
Yes, with diffuse peritonitis 1025 (39.1) 300 (36.2) 234 (35.7) 491 (43.2) 0.001
1708
or carbapenem resistance, this covariate became signifi-
cantly associated with mortality (Supplement-9).
Discussion
This multicenter observational study provided epidemio-
logical insights in critically ill patients with intra-abdom-
inal infection. The multicentre input of sequential cases 
of intra-abdominal infection offers a global view of the 
case mix of different presentations of intra-abdominal 
infection requiring ICU admission or occurring within 
the framework of an ICU stay. In spite of clinical het-
erogeneity, the core characteristics of intra-abdominal 
infection are quite generic including anatomical dis-
ruption and polymicrobial infection. Because of the 
broad variety in intra-abdominal infections, data were 
described according to a new classification based on 
setting of acquisition, presence of anatomical disrup-
tion, and severity of disease. Irrespective of type of 
Table 2 Proportion of types of intra-abdominal infection and distribution according to origin of infection acquisition
PD-related peritoneal dialysis-related
*% Within column; **% within row
Type of abdominal sepsis Total n (%)* Community-acquired 
n (%)**
Early onset hospital-
acquired n (%)**
Late-onset 
hospital-acquired 
n (%)**
Primary peritonitis 103 (3.9) 33 (32) 28 (27.2) 42 (40.8)
Secondary and tertiary peritonitis 1794 (68.4) 588 (32.8) 431 (24) 775 (43.2)
PD‑related peritonitis 9 (0.3) 0 2 (20) 7 (70)
Intra‑abdominal abscess 180 (6.9) 36 (20) 49 (27.2) 95 (52.8)
Biliary tract infection 319 (12.2) 117 (36.7) 95 (29.8) 107 (33.5)
Pancreatic infection 165 (6.3) 45 (27.3) 33 (20) 87 (52.7)
Typhlitis 9 (0.3) 0 3 (33.3) 6 (66.6)
Toxic megacolon 42 (1.6) 9 (21.4) 15 (35.7) 18 (42.9)
Total cohort
n=2621
Peri-operative
cultures
1316 (50.2)*
Trans-abdominal
needle aspiration
308 (11.8)*
Blood
cultures
1198 (45.7)*
Abdominal
drains
344 (13.2)*
No cultures sampled
639 (24.4%)
Cultures positive
1079 (82.0)
Cultures positive
250 (81.2)
Cultures positive
586 (48.9)
Cultures positive
281 (81.7)
1594 patients culture positive / 1982 patients sampled (80.4)
*% from total cohort (n=2621)
Fig. 1 Types of microbiological cultures sampled and culture‑positive rate in patients with intra‑abdominal infection
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Table 3 Micro-organisms isolated from cultures sampled in patients with intra-abdominal infection
Micro-organism Total cohort 
(n = 1982)
Setting of infection acquisition
Community-acquired 
(n = 664)
Early onset hospital-
acquired (n = 482)
Late-onset 
hospital-acquired 
(n = 836)
Gram‑negative bacteria 1161 (58.6) 385 (58) 287 (59.5) 498 (58.5)
 Enterobacterales 1024 (51.7) 344 (51.8) 247 (51.2) 433 (51.8)
  Citrobacter sp. 21 (1.1) 6 (0.9) 8 (1.7) 7 (0.8)
  Citrobacter freundii 18 (0.9) 6 (0.9) 3 (0.6) 9 (0.9)
  Escherichia coli 729 (36.8) 252 (38) 172 (35.7) 304 (36.4)
  Enterobacter aerogenes 37 (1.9) 15 (2.3) 6 (1.2) 16 (1.9)
  Enterobacter cloacae 80 (4) 31 (4.7) 16 (3.3) 34 (4.1)
  Hafnia alvei 8 (0.4) 3 (0.5) 2 (0.4) 3 (0.4)
  Morganella morganii 25 (1.3) 10 (1.5) 5 (1) 10 (1.2)
  Klebsiella sp. 51 (2.6) 22 (3.3) 12 (2.5) 17 (2)
  Klebsiella oxytoca* 44 (2.2) 23 (3.5) 11 (2.3) 10 (1.2)
  Klebsiella pneumoniae 170 (8.6) 57 (8.6) 37 (7.7) 76 (9.1)
  Proteus sp. 23 (1.2) 9 (1.4) 7 (1.5) 7 (0.8)
  Proteus mirabilis 63 (3.2) 28 (4.2) 15 (3.1) 20 (2.4)
  Providencia sp. 3 (0.2) 0 1 (0.2) 2 (0.2)
  Salmonella enterica 4 (0.2) 2 (0.3) 2 (0.4) 0
  Serratia marcescens 12 (0.6) 2 (0.3) 4 (0.8) 6 (0.7)
  Enterobacterales, other 24 (1.2) 7 (1.1) 5 (1) 12 (1.4)
 Non‑fermenting bacteria 233 (11.8) 72 (10.8) 66 (13.7) 95 (11.4)
  Pseudomonas aeruginosa 131 (6.6) 41 (6.2) 34 (7.1) 56 (6.7)
  Pseudomonas sp. (other or NI) 15 (0.8) 3 (0.5) 4 (0.8) 8 (1)
  Stenotrophomonas maltophilia 11 (0.6) 5 (0.8) 2 (0.4) 4 (0.5)
  Acinetobacter baumannii 61 (6.2) 18 (2.7) 22 (4.6) 21 (2.5)
  Acinetobacter sp. (other or NI) 32 (1.6) 8 (1.2) 12 (2.5) 12 (1.4)
 Other Gram‑negative bacteria
 Haemophilus influenzae 4 (0.2) 2 (0.3) 0 2 (0.2)
Gram‑positive bacteria 781 (39.4) 274 (41.3) 187 (38.8) 320 (38.3)
 Staphylococci 195 (9.8) 69 (10.4) 44 (9.1) 82 (9.8)
  Staphylococcus aureus 64 (3.2) 23 (3.5) 19 (3.9) 22 (2.6)
  Coagulase‑negative staphylococci 100 (5) 37 (5.6) 23 (4.8) 40 (4.8)
  Staphylococcus sp. (other or NI) 37 (1.9) 11 (1.7) 5 (1) 21 (2.5)
 Enterococci 513 (25.9) 173 (26.1) 121 (25.1) 219 (26.2)
  Enterococcus faecalis 257 (13) 83 (12.5) 59 (12.2) 115 (13.8)
  Enterococcus faecium 216 (10.9) 70 (10.5) 46 (9.5) 100 (12)
  Enterococcus sp. (other or NI) 77 (3.9) 33 (5) 18 (3.7) 26 (3.1)
 Other Gram‑positive bacteria
  Streptococcus Group A, B, C, G 117 (5.9) 44 (6.6) 27 (5.6) 46 (5.5)
  Streptococcus pneumoniae 9 (0.5) 4 (0.6) 2 (0.4) 3 (0.4)
  Streptococcus viridans 33 (1.7) 13 (2) 7 (1.5) 13 (1.6)
  Corynebacterium 8 (0.4) 1 (0.2) 3 (0.6) 4 (0.5)
Anaerobe bacteria 231 (11.7) 83 (12.5) 45 (9.3) 103 (12.3)
 Clostridium perfringens 21 (1.1) 7 (1.1) 3 (0.6) 11 (1.3)
 Peptostreptococcus sp. 4 (0.2) 1 (0.2) 2 (0.4) 1 (0.1)
 Actinomyces sp. 2 (0.1) 1 (0.2) 0 1 (0.1)
 Gram‑positive anaerobe sp. (other or NI) 53 (2.7) 17 (2.6) 12 (2.5) 24 (2.9)
 Clostridium difficile 8 (0.4) 3 (0.5) 1 (0.2) 4 (0.5)
 Bacteroides sp.* 103 (5.2) 46 (6.9) 17 (3.5) 40 (4.8)
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intra-abdominal infection, mortality was higher in late-
onset hospital-acquired cases with diffuse peritonitis and 
septic shock. This classification allows comparison across 
a spectrum of intra-abdominal infections and might be 
used for including patients in future clinical trials.
There were no differences in the prevalence of antimi-
crobial resistance in microbiological cultures sampled 
in community-acquired vs. early onset vs. late-onset 
hospital-acquired infection. This may be explained at 
least in part by the spread of resistance clones/genes 
into the community, as is the case for ESBL-producing 
or carbapenem-resistant Enterobacterales (formerly 
known as Enterobacteriaceae). This is certainly the case 
for risk regions such as Eastern and South-East Europe, 
the Middle-East, and Latin America, and matches with 
the results of a global point prevalence study on antimi-
crobial consumption and resistance [17]. This confirms 
the trend that classic risk factors for antimicrobial resist-
ance involvement are losing predictive value as illustrated 
in a multicenter study reporting antimicrobial resistance 
in 39% of infections in patients without an obvious risk 
profile as evidenced by prior antibiotic exposure and/or 
hospitalisation [18]. This observation is highly relevant as 
it might stress the need for last-line antimicrobial ther-
apy in community-acquired infection in selected regions. 
Considering local ecology together with the individual 
patient profile, and disease severity remains essential. 
However, antimicrobial resistance in key-pathogens iso-
lated in intra-abdominal infection does not seem to be 
associated with increased virulence, as it occurred at 
similar rates in infection, sepsis, and septic shock. Over-
all prevalence of enterococci was 26% and thereby sub-
stantially higher as previously reported [19–22]. This 
trend can be attributed to the steadily emergence of ente-
rococci in acute care settings or to the particular compo-
sition of a cohort of exclusively critically ill patients [23].
No differences in empiric antibacterial regimens were 
observed according to setting of infection acquisition. 
Anti-pseudomonal coverage was provided up-front in 
not only late-onset cases, a supposed classic risk factor 
for antimicrobial resistant infection, including P. aer-
uginosa strains, but also in community-acquired or early 
onset hospital-acquired infections. This is probably trig-
gered by a safety-reflex in physicians, not to miss any 
potential pathogen, especially P. aeruginosa strains. Thus, 
the risk factor-based antibiotic strategy that appears in 
all guidelines seems not to be implemented in a large 
real-life sample of intra-abdominal infection in the ICU, 
reflecting response to severity.
It is reassuring that the vast majority of intra-abdom-
inal infections in the ICU were approached by an early 
source control intervention. It has been established that 
surgery needs to be performed after hemodynamic stabi-
lization, but nevertheless should be performed as early as 
possible aiming at damage control [24]. The importance 
of source is evidenced by the increased mortality among 
patients with persistent inflammation or need for addi-
tional surgical intervention.
Table reports n patients positive (% of total number of patients with cultures sampled)
NI not identified
*p < 0.05 for differences between setting of infection acquisition
Table 3 (continued)
Micro-organism Total cohort 
(n = 1982)
Setting of infection acquisition
Community-acquired 
(n = 664)
Early onset hospital-
acquired (n = 482)
Late-onset 
hospital-acquired 
(n = 836)
 Porphyromonas sp. 2 (0.1) 0 2 (0.4) 0
 Prevotella sp. 5 (0.3) 3 (0.5) 0 2 (0.2)
 Fusobacterium sp. 9 (0.5) 7 (1.1) 0 2 (0.2)
 Gram‑negative anaerobe sp. (other or NI) 66 (3.3) 20 (3) 13 (2.7) 33 (3.9)
Fungi 258 (13) 80 (12) 71 (14.7) 107 (12.8)
 Aspergillus sp. 3 (0.2) 0 2 (0.4) 1 (0.1)
 Candida sp. 257 (13) 81 (12.2) 69 (14.3) 107 (12.8)
  Candida albicans 173 (8.7) 56 (8.4) 50 (10.4) 67 (8)
  Candida glabrata 35 (1.8) 10 (1.5) 9 (1.9) 16 (1.9)
  Candida krusei 3 (0.2) 2 (0.3) 0 1 (0.1)
  Candida parapsilosis 9 (0.5) 4 (0.6) 1 (0.2) 4 (0.5)
  Candida tropicalis 16 (0.8) 6 (0.9) 2 (0.4) 8 (1)
  Candida sp. (other or NI) 20 (1) 2 (0.3) 7 (1.5) 11 (1.3)
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Late-onset hospital-acquired infection, diffuse perito-
nitis, and septic shock were identified as independent risk 
factors for mortality, and confirm the robustness of the 
new classification system for risk stratification. Antimi-
crobial resistance defined as either MRSA, VRE, ESBL-
producing, or carbapenem-resistant Gram-negative 
bacteria was independently associated with increased 
mortality (Supplement-9). Surprisingly, however, the 
more strict definition of either MRSA, VRE, or difficult-
to-treat resistant Gram-negative bacteria was not associ-
ated with increased mortality. Probably, the cohort lacked 
sufficient power as in only 85 patients, difficult-to-treat 
Gram-negatives were involved vs. 341 ESBL-producing or 
carbapenem-resistant Gram-negative bacteria. We have 
no explanation for the favorable association with anti-
MRSA agents. This can hardly be due to the anti-MRSA 
Table 4 Rates of antimicrobial resistance in intra-abdominal infections according to geographic region
% Represent proportion per column; Resistance rates reflect proportion of patients in which resistant strains are isolated (e.g., n MRSA/total n patients) and do not 
represent proportion of resistance within particular pathogens (e.g., n MRSA/total S. aureus isolates)
Denominator for microbiological data includes only patients in which cultures were sampled (data from South Africa are excluded as they included only seven 
patients)
ESBL extended-spectrum beta-lactamase-producing, MRSA methicillin-resistant Staphylococcus aureus, VRE vancomycin-resistant enterococci
*Gram-negative bacteria that are either ESBL-producing, or carbapenem-resistant, or fluoroquinolone-resistant
**Total rates of multidrug resistance considering difficult-to-treat resistant Gram-negative bacteria, MRSA, and VRE
***Total rates of multidrug resistance considering any type of Gram-negative resistance (either ESBL-producing, or carbapenem-resistant, or fluoroquinolone-resistant 
bacteria), MRSA, and VRE
Antibiotic-
resistant 
pathogen
Total 
cohort 
(n = 1982)
Geographic region
Western 
Europe 
(n = 601)
Southern 
Europe 
(n = 558)
Eastern 
and South-
East Europe 
(n = 151)
Central 
Europe 
(n = 99)
North Africa 
and Mid-
dle-East 
(n = 172)
Latin 
America 
(n = 249)
North 
America 
(n = 22)
Asia–Pacific 
(n = 123)
Difficult‑to‑
treat resist‑
ant Gram‑
negative 
bacteria
85 (4.3) 2 (0.3) 38 (6.8) 9 (6) 0 15 (8.7) 16 (6.4) 0 5 (4.1)
Any resistant 
Gram‑
negative 
bacteria*
480 (24.2) 54 (9) 140 (25.1) 59 (39.1) 20 (20.2) 82 (47.7) 90 (36.1) 7 (31.8) 26 (21.1)
 ESBL‑
producing 
Gram‑
negative 
bacteria
326 (16.4) 37 (6.2) 81 (14.5) 37 (24.5) 9 (9.1) 65 (37.8) 69 (27.7) 7 (31.8) 20 (16.3)
 Carbap‑
enem‑
resistant 
Gram‑
negative 
bacteria
145 (7.3) 3 (0.5) 61 (10.9) 23 (15.2) 1 (1) 23 (13.4) 25 (10) 0 9 (7.3)
 Fluoroqui‑
nolone‑
resistant 
Gram‑
negative 
bacteria
339 (17.1) 29 (4.8) 108 (19.4) 37 (24.5) 18 (18.2) 57 (33.1) 69 (27.7) 3 (13.6) 17 (13.8)
MRSA 20 (1) 1 (0.2) 5 (0.9) 5 (3.3) 0 5 (2.9) 3 (1.2) 0 1 (0.8)
VRE 56 (2.8) 11 (1.8) 15 (2.7) 5 (3.3) 2 (2) 9 (5.2) 11 (4.4) 1 (4.5) 2 (1.6)
Antimicrobial 
resistance** 
(total)
153 (7.7) 14 (2.3) 57 (10.2) 16 (10.6) 2 (2) 29 (16.9) 27 (10.8) 1 (4.5) 7 (5.7)
Antimicrobial 
resist‑
ance*** 
(total)
522 (26.3) 63 (10.5) 152 (27.2) 65 (43) 21 (21.2) 87 (50.6) 96 (38.6) 8 (36.4) 28 (22.8)
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activity as such, since MRSA was isolated in only 20 
patients. The advantageous association might be due to 
the anti-enterococcal activity of these agents. Yet, entero-
coccal coverage as such (not necessarily covering MRSA) 
was not retained in the final regression model assess-
ing relationships with mortality. Hence, this observation 
might just be an incidental finding. On the other hand, 
the absence of an association between empiric antifungal 
therapy and outcome seems consistent with the finding 
of other cohort studies and randomized-controlled trials 
that did not demonstrate the effect of empirical Candida 
coverage and favorable outcome [25, 26].
Legend: Several types of source control interventions could have been executed in a single patient.
Fig. 2 Initial approach to control the source of infection. Several types of source control interventions could have been executed in a single patient
Table 5 Mortality according to alternative classification of intra-abdominal infection
Severity 
of disease 
expression
Setting of infection acquisition
Community-acquired Early onset hospital-acquired Late-onset hospital-acquired
 Septic shock 18/64
28.1%
25/83
30.1%
48/101
47.5%
21/63
33.3%
13/61
21.3%
37/91
40.7%
45/103
43.7%
48/110
43.6%
94/190
49.5%
 Sepsis 13/116
11.2%
42/221
19%
37/174
21.3%
27/90
30%
33/170
19.4%
43/128
33.6%
26/147
17.7%
62/237
26.2%
99/275
36%
 Infection 1/7
14.3%
3/22
13.6%
4/22
18.2%
0/7
0%
0/21
0%
2/14
14.3%
1/12
8.3%
8/36
22.2%
2/23
8.7%
No Yes, with 
localized 
peritonitis
Yes, with 
diffuse 
peritonitis
No Yes, with 
localized 
peritonitis
Yes, with 
diffuse 
peritonitis
No Yes, with 
localized 
peritonitis
Yes, with 
diffuse 
peritonitis
Anatomical disruption Anatomical disruption Anatomical disruption
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This study has limitations. This is an observational 
cohort study disposed to confounding. Some geographic 
regions are poorly represented obstructing conclu-
sive results. Evaluation of source control achievement 
remains a subjective appreciation performed by the 
attending physician; given the study scale, it was not 
feasible to establish an independent panel for in-depth 
evaluation of source control as previously reported [27]. 
At the same line, given the observational study design, 
there was no predefined approach to source control [7]. 
In addition, with this paper, we intended to provide a 
general epidemiological snapshot. Therefore, detailed 
country-specific or disease-specific analyses fell outside 
the scope of this report. Finally, we could not report the 
proportion of ICU patients with intra-abdominal infec-
tion/sepsis as the total number of admissions during the 
inclusion of cases was not recorded.
In conclusion, this multinational cohort of ICU patients 
with intra-abdominal infection revealed that late-onset 
healthcare-associated infection, diffuse peritonitis, and 
sepsis or septic shock are independent risk factors for 
mortality. Therefore, setting of infection acquisition, ana-
tomical disruption, and severity of disease expression are 
disease-specific phenotypic characteristics associated 
with outcome, irrespective of the type of intra-abdominal 
infection. Antimicrobial resistance is mainly an issue of 
Gram-negatives and a particular concern in specific geo-
graphic areas and associated with worse outcome as was 
failure of source control.
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Table 6 Independent relationships with mortality in critically ill patients with intra-abdominal infection
The variable “antimicrobial resistance” defined as either MRSA, vancomycin-resistant enterococci (VRE), or difficult-to-treat resistant Gram-negative bacteria did not 
achieve the final regression model. Supplement-9 reports the results of the logistic regression models with antibiotic resistance defined as either MRSA, VRE, ESBL-
producing, or carbapenem-resistant Gram-negative bacteria. In these logistic regression models, antibiotic resistance was associated with increased risk of mortality, 
while other covariates remained stable
OR odds ratio, CI confidence interval, MRSA methicillin-resistant Staphylococcus aureus
*Area under the receiver-operating curve characteristic: 0.778; **Area under the receiver-operating curve characteristic: 0.689
Variable Model with source control achievement*
OR (95% CI)
Model without source 
control achievement**
OR (95% CI)
Setting of infection acquisition
 Community‑acquired infection Reference Reference
 Early onset hospital‑acquired infection (≤ 7 days) 1.15 (0.84–1.58) 1.18 (0.88–1.59)
 Late‑onset hospital‑acquired infection (> 7 days) 1.76 (1.34–2.32) 1.76 (1.36–2.30)
Anatomical disruption
 No anatomical barrier disruption Reference Reference
 Anatomical disruption with localized peritonitis 1.28 (0.95–1.75) 1.26 (0.95–1.69)
 Anatomical disruption with diffuse peritonitis 1.99 (1.49–2.67) 2.04 (1.55–2.70)
Severity of disease expression
 Infection Reference Reference
 Sepsis 2.44 (1.37–4.66) 2.28 (1.31–4.28)
 Septic shock 5.22 (2.91–10) 4.93 (2.80–9.30)
Age (per year increase) 1.03 (1.02–1.04) 1.03 (1.03–1.04)
Underlying conditions
 Malnutrition (body mass index < 20) 2.07 (1.34–3.17) 2.15 (1.43–3.21)
 Diabetes mellitus 1.31 (0.99–1.73) 1.32 (1.01–1.72)
 Liver failure 2.03 (1.23–3.33) 2.50 (1.55–4.02)
 Congestive heart failure 1.86 (1.24–2.81) 1.92 (1.31–2.81)
Empiric antimicrobial coverage
 Anti‑MRSA agent 0.77 (0.59–1) 0.77 (0.59–0.98)
 Double anaerobe coverage – 1.28 (0.97–1.71)
Source control achievement at day 7
 Success Reference –
 Failure, persistent signs of inflammation 4.85 (3.79–6.22) –
 Failure, additional intervention required following initial approach 1.93 (1.41–2.65) –
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